NEW YORK (GenomeWeb News) – Investment bank ISI Group this week downgraded shares of PerkinElmer and upgraded shares of Danaher.

In a research note, analyst Ross Muken lowered the rating for PerkinElmer to Neutral from Buy, saying that the company's stock is "now approaching the upper end of its historical range, and therefore we see limited opportunity for multiple expansion." He maintained a $49 price target on PerkinElmer's shares.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.